A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2972-2983

  Zhong, Lei ^a   Fu, Xiao Yu ^b   Zou, Chan ^a   Yang, Ling Ling ^a   Zhou, Shu ^a   Yang, Jiao ^a   Tang, Yun ^b   Cheng, Chuan ^a   Li, Lin Li ^b   Xiang, Rong ^c   Chen, Li Juan ^a   Chen, Yu Zong ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

Anti angiogenesis; Hepatocellular carcinoma; Multi kinase inhibitor; SKLB 329; Src

Indexed keywords

1-(4-((1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-YL)OXY)-2-FLUOROPHENYL)-3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREA; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SORAFENIB;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; HUMAN; IC50; LIVER; LIVER NEOPLASMS; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRAZOLES; SIGNAL TRANSDUCTION; ZEBRAFISH;

EID: 84908681009     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28944     Document Type: Article

References (43)

1. Alves RC, Alves D, Guz B, et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011;10:21-7.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020-2.
3. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now. Clin Cancer Res 2010;16:390-7.
4. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013;5: 345-52.
5. Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011;337:155-61.
6. Ezzoukhry Z, Louandre C, Trecherel E, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012;131: 2961-9.
7. Lu JJ, Pan W, Hu YJ, et al. Multi-target drugs: the trend of drug research and development. PloS One 2012;7:e40262.
8. Shimizu S, Takehara T, Hikita H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012;131: 548-57.
9. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12: 34-42.
10. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8.
11. Wang L, Park H, Chhim S, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 2012;11:864- 72.
12. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010;223:14-26.
13. Sanchez-Bailon MP, Calcabrini A, Gomez- Dominguez D, et al. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal 2012;24:1276-86.
14. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011;2011:865819.
15. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Srcdependent survival signals. Cancer cell 2009;16: 67-78.
16. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011;16:566-78.
17. Chen ML, Chai CY, Yeh KT, et al. Crosstalk between activated and inactivated c-Src in hepatocellular carcinoma. Dis Markers 2011;30:325- 33.
18. Ito Y, Kawakatsu H, Takeda T, et al. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J Hepatol 2001; 35:68-73.
19. Lau GM, Yu GL, Gelman IH, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 2009;54: 1465-74.
20. Pan Y, Xu Y, Feng S, et al. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 2012;11:952-62.
21. Zhang S, Cao Z, Tian H, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 2011;17:4439-50.
22. Cao ZX, Zheng RL, Lin HJ, et al. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol Biochem 2011; 27:565-74.
23. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101:1717-23.
24. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
25. Wilhelm SM, Carter C, Tang L, et al. BAY 43- 9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109.
26. Wei G, Wang M, Hyslop T, et al. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 2010;127:2949-58.
27. Zhang B, Liu L, Zhao S, et al. Vitexicarpin acts as a novel angiogenesis inhibitor and its target network. Evid Based Complement Alternat Med 2013;2013:278405.
28. Camus S, Quevedo C, Menéndez S, et al. Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish. Oncogene 2012;31:4333-42.
29. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383- 88.
30. Zahang S, Huang WC, Zhang L, et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res 2013;73: 5764-74.
31. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19: 5636-42.
32. Hoamsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007;11:91-100.
33. Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003;39:1447-55.
34. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9.
35. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
36. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human ancreatic carcinoma. Biochem Biophys Res Commun 1998;243: 503-8.
37. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS- 354825), on human prostate cancer cells. Cancer Res 2005;65: 9185-89.
38. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-95.
39. Araujo JL, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010;36: 492-500.
40. Aleshin AL, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010;12:599-607.
41. Gelman IH. Src-family tyrosine kinases as therapeutic targets in advanced cancer. Front Biosci 2011;3:801-7.
42. Chang AY, Wang M. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 2013;13:267.
43. Finn RS, Aleshin A, Dering J, et al. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013;57: 1838-46.